Trial · NCT03022747
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-thioguanine (6TG) levels in erythrocytes | Up to week 25 | The fraction of patients with 6TG levels over 200 nmol/mmol Hb at week 13 and 25 (ie after 12 weeks standard and allopurinol treatment respectively) |
| Secondary | Mean level of 6-thioguanine | Up to week 25 | The mean level of 6TG at week 13 and 25 |
| Secondary | Mean level of DNA-incorporated thioguanine (DNA-TGN) | Up to week 25 | The mean level of DNA-TGN at week 13 and 25 |
| Secondary | Mean level of 6-methylmercaptopurine (6MMP) | Up to week 25 | The mean level of 6MMP at week 13 and 25 |
| Secondary | Mean levels of platelets | Up to week 25 | Comparison of weighted mean of platelets in the treatment phases |
| Secondary | Mean levels of hemoglobin | Up to week 25 | Comparison of weighted mean of hemoglobin in the treatment phases |
| Secondary | Mean levels of absolute neutrophil count (ANC) | Up to week 25 | Comparison of weighted mean of ANC in the treatment phases |
| Secondary | Mean levels of white blood cells (WBC) | Up to week 25 | Comparison of weighted mean of WBC in the treatment phases |
| Secondary | Glutamate pyruvate transaminase (GPT) | Up to week 25 | Comparison of weighted means of serum GPT in the treatment phases |
| Secondary | Bilirubin | Up to week 25 | Comparison of weighted means of serum bilirubin in the treatment phases |
| Secondary | Hypoglycemia | Up to week 25 | Comparison of incidence of hypoglycemia and laboratory measures of metabolic disturbance during the treatment phases |
| Secondary | Metabolic disturbance | Up to week 25 | Comparison of incidence of laboratory measures of metabolic disturbance during the treatment phases |
| Secondary | Incidence of serious adverse events (SAE) | Up to week 29 | Comparison of the frequency of SAE in the treatment phases |
| Secondary | Cumulative dose of 6-mercaptopurine and methotrexate | Up to week 29 | Comparison of the cumulative dose of 6MP and methotrexate and days with treatment interruption in the two treatment arms |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03022747/registered